Quick Answer
Evommune, Inc. reported Operating Income of -$81.07 million for fiscal year 2025.
Evommune, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$81.07M | -15.8% |
| 2024 | -$70.01M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$13.33M | +19.3% | +19.3% |
| September 30, 2024 | -$16.52M | — | — |
- Evommune, Inc. showed a decrease of -15.8% in Operating Income compared to the prior fiscal year.
- Over the 2024–2025 period, Evommune, Inc.’s operating income has declined by 15.8% (from -$70.01 million to -$81.07 million).
- The most recent figure is from Evommune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: